DE2837168A1
(de)
|
1978-08-25 |
1980-03-06 |
Blutspendedienst Dt Rote Kreuz |
Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung
|
US4362661A
(en)
|
1979-08-09 |
1982-12-07 |
Teijin Limited |
Immunoglobulin composition having a high monomer content, and process for production thereof
|
US4360457A
(en)
|
1979-08-30 |
1982-11-23 |
Teijin Limited |
S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
|
US4374763A
(en)
|
1979-09-17 |
1983-02-22 |
Morishita Pharmaceutical Co., Ltd. |
Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
|
US4396608A
(en)
|
1981-08-24 |
1983-08-02 |
Cutter Laboratories |
Intravenously injectable immune serum globulin
|
US5702699A
(en)
|
1982-09-23 |
1997-12-30 |
Cetus Corporation |
Process for the recovery of lipophilic proteins
|
US4681713A
(en)
|
1984-03-15 |
1987-07-21 |
Toyo Boseki Kabushiki Kaisha |
Method of making a hollow fiber membrane for dialysis
|
US4597966A
(en)
|
1985-01-09 |
1986-07-01 |
Ortho Diagnostic Systems, Inc. |
Histidine stabilized immunoglobulin and method of preparation
|
US6673347B1
(en)
|
1986-04-30 |
2004-01-06 |
Gryphon Therapeutics |
Polypeptide and protein derivatives and process for their preparation
|
GB8628104D0
(en)
|
1986-11-25 |
1986-12-31 |
Connaught Lab |
Pasteurization of immunoglobin solutions
|
DE3640513A1
(de)
|
1986-11-27 |
1988-06-09 |
Biotest Pharma Gmbh |
Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
|
JP2547556B2
(ja)
|
1987-02-06 |
1996-10-23 |
株式会社 ミドリ十字 |
r−グロブリンの液状製剤
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
DK0939121T4
(da)
|
1989-09-12 |
2008-02-04 |
Ahp Mfg B V |
TNF-bindende proteiner
|
DE3939346A1
(de)
|
1989-11-29 |
1991-06-06 |
Behringwerke Ag |
Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
|
US5177194A
(en)
|
1990-02-01 |
1993-01-05 |
Baxter International, Inc. |
Process for purifying immune serum globulins
|
US5945098A
(en)
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
GB9017002D0
(en)
|
1990-08-02 |
1990-09-19 |
Health Lab Service Board |
Improved method for the purification of erwina l-asparaginase
|
JP3179538B2
(ja)
|
1990-12-11 |
2001-06-25 |
ノバルティス アクチエンゲゼルシャフト |
安定なヒトカルシトニンの水性溶液
|
US5110910A
(en)
|
1991-03-25 |
1992-05-05 |
Miles Inc. |
Virucidal euglobulin precipitation
|
US5256571A
(en)
|
1991-05-01 |
1993-10-26 |
Cytyc Corporation |
Cell preservative solution
|
CA2126182C
(en)
|
1991-12-20 |
2001-07-17 |
Man S. Co |
Humanized antibodies reactive with gpiib/iiia
|
US6004555A
(en)
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US5298410A
(en)
|
1993-02-25 |
1994-03-29 |
Sterling Winthrop Inc. |
Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
DE4344824C1
(de)
|
1993-12-28 |
1995-08-31 |
Immuno Ag |
Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
|
GB9401448D0
(en)
|
1994-01-26 |
1994-03-23 |
Ciba Geigy Ag |
Stable dry powders
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
AU3272695A
(en)
|
1994-08-12 |
1996-03-07 |
Immunomedics Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
SI9720020B
(en)
|
1996-02-09 |
2001-12-31 |
Basf Ag |
Human antibodies that bind human TNF alpha
|
TWI240627B
(en)
|
1996-04-26 |
2005-10-01 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
WO1998003550A1
(en)
|
1996-07-18 |
1998-01-29 |
Csl Limited |
Pasteurization of immunoglobulin solutions
|
TW491855B
(en)
|
1996-08-07 |
2002-06-21 |
Csl Ltd |
Purification of immunoglobulins
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US5886154A
(en)
|
1997-06-20 |
1999-03-23 |
Lebing; Wytold R. |
Chromatographic method for high yield purification and viral inactivation of antibodies
|
JP3679406B2
(ja)
|
1998-05-20 |
2005-08-03 |
協和醗酵工業株式会社 |
遺伝子組換え抗体
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
WO2001060397A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
JP4685238B2
(ja)
|
1998-06-09 |
2011-05-18 |
ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト |
静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
|
US6610206B1
(en)
|
1998-10-20 |
2003-08-26 |
Advanced Renal Technologies |
Buffered compositions for dialysis
|
IL127127A0
(en)
|
1998-11-18 |
1999-09-22 |
Peptor Ltd |
Small functional units of antibody heavy chain variable regions
|
US7294481B1
(en)
|
1999-01-05 |
2007-11-13 |
Immunex Corporation |
Method for producing recombinant proteins
|
NZ551331A
(en)
|
1999-02-03 |
2008-08-29 |
Amgen Inc |
Methods using polypeptides involved in immune response
|
CA2369451C
(en)
|
1999-04-08 |
2009-09-22 |
Genentech, Inc. |
Composition based on oppositely-charged polypeptides
|
ATE401908T1
(de)
|
1999-04-09 |
2008-08-15 |
Ortho Mcneil Pharm Inc |
Pharmazeutische zusammensetzungen von erythropoietin
|
EP1171148A2
(en)
|
1999-04-19 |
2002-01-16 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical desorders
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
HUP0203133A3
(en)
|
1999-10-04 |
2005-07-28 |
Chiron Corp Emeryville |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
ATE403437T1
(de)
|
1999-12-14 |
2008-08-15 |
Genentech Inc |
Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
|
AR026946A1
(es)
|
1999-12-16 |
2003-03-05 |
Amgen Inc |
Osteoprotegerina/receptores de factores de necrosis de tumores
|
MXPA02007683A
(es)
|
2000-02-10 |
2002-12-13 |
American Home Prod |
Metodo para tratar o inhibir la lesion celular o muerte celular.
|
AU2002224555A1
(en)
|
2000-07-25 |
2002-02-05 |
Takeda Chemical Industries Ltd. |
Process for producing recombinant protein
|
WO2002011753A1
(fr)
|
2000-08-04 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Preparations proteiniques a injecter
|
PT1314437E
(pt)
|
2000-08-11 |
2014-08-29 |
Chugai Pharmaceutical Co Ltd |
Preparações estabilizadas contendo anticorpo
|
IL155002A0
(en)
|
2000-10-12 |
2003-10-31 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
JP2004515243A
(ja)
|
2000-12-14 |
2004-05-27 |
藤沢薬品工業株式会社 |
サイレント抗cd28抗体およびその使用
|
US6693173B2
(en)
|
2000-12-26 |
2004-02-17 |
Alpha Therapeutic Corporation |
Method to remove citrate and aluminum from proteins
|
HUP0302525A2
(hu)
|
2001-01-05 |
2003-10-28 |
Abgenix, Inc. |
Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
|
ES2184594B1
(es)
|
2001-01-17 |
2004-01-01 |
Probitas Pharma Sa |
Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
|
SK10472003A3
(sk)
|
2001-02-23 |
2004-03-02 |
Immunex Corporation |
Zvýšený výťažok aktívnych proteínov
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
KR20030036722A
(ko)
|
2001-06-25 |
2003-05-09 |
코닌클리즈케 필립스 일렉트로닉스 엔.브이. |
고압 가스 방전 램프 및 그 제조 방법
|
CA2451955C
(en)
|
2001-06-26 |
2015-09-29 |
Abgenix, Inc. |
Antibodies to opgl
|
AU2002332628B2
(en)
*
|
2001-08-23 |
2007-07-26 |
Genmab A/S |
Human antibodies specific for interleukin 15 (IL-15)
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
WO2003024388A2
(en)
|
2001-09-20 |
2003-03-27 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
|
KR100913714B1
(ko)
|
2001-11-08 |
2009-08-24 |
패시트 바이오테크 코포레이션 |
Igg 항체의 안정한 액상 약학 제형물
|
AU2002359495A1
(en)
|
2001-11-30 |
2003-06-17 |
Centocor, Inc. |
Anti-tnf antibodies, compositions, methods and uses
|
CA2469815C
(en)
|
2001-12-21 |
2011-05-03 |
Immunex Corporation |
Methods for purifying protein
|
KR101080021B1
(ko)
|
2002-02-14 |
2011-11-04 |
추가이 세이야쿠 가부시키가이샤 |
항체함유 용액제제
|
EP1485130A4
(en)
|
2002-02-21 |
2006-11-22 |
Univ Duke |
REAGENTS AND TREATMENT PROCEDURES FOR AUTOIMMUNE DISEASES
|
WO2003072060A2
(en)
|
2002-02-27 |
2003-09-04 |
Immunex Corporation |
Polypeptide formulation
|
PL376821A1
(pl)
|
2002-03-27 |
2006-01-09 |
Immunex Corporation |
Sposoby zwiększania produkcji polipeptydów
|
CA2481074A1
(en)
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US7323553B2
(en)
|
2002-04-26 |
2008-01-29 |
Genentech, Inc. |
Non-affinity purification of proteins
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
EP1551875A4
(en)
|
2002-06-21 |
2006-06-28 |
Biogen Idec Inc |
TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
|
NZ555692A
(en)
|
2002-07-19 |
2009-02-28 |
Abbott Biotech Ltd |
Treatment of TNF alpha related disorders
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
CA2504134C
(en)
|
2002-11-01 |
2012-03-06 |
Bayer Healthcare Llc |
Process for concentration of macromolecules
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
ATE496938T1
(de)
|
2002-12-20 |
2011-02-15 |
Amgen Inc |
Myostatin hemmende bindungsstoffe
|
BRPI0408317A
(pt)
|
2003-03-14 |
2006-03-07 |
Pharmacia Corp |
anticorpos do receptor de igf-i para o tratamento de cáncer
|
RU2332986C2
(ru)
|
2003-04-04 |
2008-09-10 |
Дженентек, Инк. |
Высококонцентрированные композиции антител и белков
|
DK1624864T3
(en)
|
2003-05-14 |
2015-02-23 |
Danisco Us Inc |
Controlled release of active agents by the use of the repeat sequence protein polymers
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
PL1639011T3
(pl)
|
2003-06-30 |
2009-05-29 |
Domantis Ltd |
Pegilowane przeciwciała jednodomenowe (dAb)
|
TWI356064B
(en)
|
2003-11-07 |
2012-01-11 |
Immunex Corp |
Antibodies that bind interleukin-4 receptor
|
EP1532983A1
(en)
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
JP2007522157A
(ja)
|
2004-02-12 |
2007-08-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
抗egfr抗体の高濃縮液体製剤
|
WO2005095454A1
(en)
|
2004-03-25 |
2005-10-13 |
Diadexus, Inc. |
Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk
|
US8333995B2
(en)
|
2004-05-12 |
2012-12-18 |
Baxter International, Inc. |
Protein microspheres having injectable properties at high concentrations
|
WO2006003999A1
(ja)
|
2004-07-05 |
2006-01-12 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
|
JP5015774B2
(ja)
*
|
2004-07-29 |
2012-08-29 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジフルオロ置換複素環化合物および液晶媒体における構成要素としてのその使用
|
TW200621282A
(en)
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
TWI364458B
(en)
|
2004-08-27 |
2012-05-21 |
Wyeth Res Ireland Ltd |
Production of tnfr-lg
|
US20080312425A1
(en)
|
2004-08-30 |
2008-12-18 |
Lonza Biologics Plc. |
Ion Exchange Chromatography and Purification of Antibodies
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
WO2006064373A2
(en)
|
2004-12-16 |
2006-06-22 |
Genzyme Polyclonals S.A.S. |
Methods of purifying immunologlobulins
|
JP4498939B2
(ja)
|
2005-02-01 |
2010-07-07 |
東京応化工業株式会社 |
ポジ型レジスト組成物およびレジストパターン形成方法
|
US8597709B2
(en)
|
2005-04-12 |
2013-12-03 |
Inovobiologic Inc. |
Dietary supplement and methods of use
|
EP1909831A4
(en)
|
2005-06-14 |
2013-02-20 |
Amgen Inc |
PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070049732A1
(en)
|
2005-09-01 |
2007-03-01 |
Zurlo Eugene J |
Ultra-high yield intravenous immune globulin preparation
|
ZA200803448B
(en)
|
2005-09-21 |
2009-10-28 |
Burcon Nutrascience Mb Corp |
Preparation of canola protein isolate involving isoelectric precipitation
|
US8067350B2
(en)
|
2005-12-15 |
2011-11-29 |
Kimberly-Clark Worldwide, Inc. |
Color changing cleansing composition
|
US20070202051A1
(en)
|
2006-02-10 |
2007-08-30 |
Pari Gmbh |
Aerosols for sinunasal drug delivery
|
EP2021030A2
(en)
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
EA018301B1
(ru)
|
2006-04-21 |
2013-07-30 |
Новартис Аг |
Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
|
CA2663416A1
(en)
|
2006-09-15 |
2008-03-20 |
Barofold, Inc. |
High pressure treatment of proteins for reduced immunogenicity
|
MX2009004351A
(es)
|
2006-10-27 |
2009-05-12 |
Abbott Biotech Ltd |
Anticuerpos anti-htnfalfa cristalinos.
|
JP5577098B2
(ja)
|
2006-12-21 |
2014-08-20 |
アムジエン・インコーポレーテツド |
ポリペプチドを含有する安定な緩衝化された製剤
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
NZ709704A
(en)
|
2007-11-30 |
2017-03-31 |
Abbvie Biotechnology Ltd |
Protein formulations and methods of making same
|
CN102202643A
(zh)
*
|
2008-02-07 |
2011-09-28 |
安姆根有限公司 |
稳定化的蛋白组合物
|
US8052645B2
(en)
|
2008-07-23 |
2011-11-08 |
Avant Medical Corp. |
System and method for an injection using a syringe needle
|
US8177749B2
(en)
|
2008-05-20 |
2012-05-15 |
Avant Medical Corp. |
Cassette for a hidden injection needle
|
JP5836120B2
(ja)
|
2008-05-20 |
2015-12-24 |
アヴァント・メディカル・コーポレーション |
オートインジェクタシステム
|
CN102159204B
(zh)
*
|
2008-09-19 |
2015-04-01 |
辉瑞公司 |
稳定的液体抗体制剂
|
CN102271707B
(zh)
*
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
CA2754528A1
(en)
|
2009-03-06 |
2010-09-10 |
Genetech, Inc. |
Antibody formulation
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
US9084849B2
(en)
|
2011-01-26 |
2015-07-21 |
Kaleo, Inc. |
Medicament delivery devices for administration of a medicament within a prefilled syringe
|
ES2759931T3
(es)
*
|
2011-04-20 |
2020-05-12 |
Sandoz Ag |
Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
|
JP6038884B2
(ja)
|
2011-04-20 |
2016-12-07 |
アムゲン・インコーポレーテッド |
自動式注射装置
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
JP6463968B2
(ja)
|
2011-07-01 |
2019-02-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法
|
WO2013059406A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Coherus Biosciences, Inc. |
Etanercept formulations stabilized with metal ions
|
RU2649473C2
(ru)
|
2012-07-05 |
2018-04-03 |
Юнитрект Сириндж Пти Лтд |
Автоматическое устройство для инъекций с инъекционным картриджем и приводной механизм такого устройства
|
EP2869817A4
(en)
*
|
2012-07-09 |
2016-04-06 |
Coherus Biosciences Inc |
STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
|
BR112015005161A2
(pt)
*
|
2012-09-11 |
2017-07-04 |
Coherus Biosciences Inc |
etanercepte corretamente dobrado em alta pureza e excelente rendimento
|
PT2919801T
(pt)
|
2012-10-26 |
2020-07-30 |
Lupin Atlantis Holdings Sa |
Composição farmacêutica estável da proteína de fusão tnfr:fc etanercept
|
EP2919812A4
(en)
*
|
2012-11-19 |
2016-05-18 |
Merck Sharp & Dohme |
Liquid formulations for TNFR: FC fusion proteins
|
CN104870019A
(zh)
*
|
2012-11-27 |
2015-08-26 |
阿特根公司 |
用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
|
CN105007896B
(zh)
|
2012-12-28 |
2019-04-09 |
雅培心血管***公司 |
包含抗体的治疗组合物
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
JP6768501B2
(ja)
|
2013-03-15 |
2020-10-14 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入機、および自動注入機システム
|
EP2991668A1
(en)
|
2013-05-02 |
2016-03-09 |
Mabxience, S.A. |
Alternative formulations for tnfr: fc fusion polypeptides
|
EP3892288A1
(en)
*
|
2013-10-24 |
2021-10-13 |
Astrazeneca AB |
Stable, aqueous antibody formulations
|
CA2930227C
(en)
|
2013-11-29 |
2021-09-28 |
Ares Trading S.A. |
A liquid formulation of a fusion protein comprising tnfr and fc region
|
EP2975050B1
(en)
|
2014-07-18 |
2019-05-29 |
Sandoz Ag |
Quantification of misfolded TNFR2:Fc
|
WO2016033496A1
(en)
|
2014-08-28 |
2016-03-03 |
Unitract Syringe Pty Ltd |
Skin sensors for drug delivery devices
|
MX2017002428A
(es)
|
2014-08-28 |
2017-05-15 |
Unitract Syringe Pty Ltd |
Sistemas de sensores para dispositivos de entrega de medicamento.
|
WO2016102328A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
EP3268042A4
(en)
|
2015-03-13 |
2018-08-01 |
Samsung Bioepis Co., Ltd. |
Anti-tnf-alpha polypeptide composition and use thereof
|
US9763976B1
(en)
|
2016-08-02 |
2017-09-19 |
Zo Skin Health, Inc. |
Composition and method for treating skin conditions
|
BR112019007858A2
(pt)
|
2016-10-21 |
2019-07-02 |
Amgen Inc |
formulações farmacêuticas e métodos para produzir as mesmas
|